Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today are proud to announce that Renée Aguiar-Lucander, CEO, Hansa Biopharma has been named one of Sweden’s Most Influential Business Women of 2026 by Dagens industri.

This nomination recognizes leaders with significant influence over the development, competitiveness and future of Swedish business. The award reflects both individual leadership and the role Hansa Biopharma plays in driving growth, innovation and competitiveness.

Renée Aguiar-Lucander, CEO, said: “I am truly honored to be named as part of this illustrious group of business leaders in Sweden by Dagens industri. Over the past eight years I have a had the amazing opportunity to build strong Sweden based internationally successful businesses within the life sciences sector, addressing unmet medical needs of patients. At Hansa we have undertaken a clear and focused transformation, strengthening our financial resilience, building a high‑performing leadership team and delivering both scientific and strategic progress. I am excited about our continued journey to deliver transformative therapies to patients, and I am grateful for this nomination and the opportunity to shine a light on the importance of Swedish entrepreneurship and innovation”

The full list of all leaders will be published in Dagens industri on June 4.

--- ENDS ---

Contacts for more information:

Kerstin Falck, VP Global Corporate Affairs
[email protected]
IR@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at  www.hansabiopharma.com  and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.